Back to Journals » Psoriasis: Targets and Therapy

Psoriasis: Targets and Therapy

ISSN: 2230-326X


Journal Articles:

- 136 records -

Therapeutic Potential of Spesolimab-Sbzo in the Management of Generalized Pustular Psoriasis Flares in Adults: Evidence to Date

Rega F, Trovato F, Bortone G, Pellacani G, Richetta AG, Dattola A

Psoriasis: Targets and Therapy 2024, 14:23-27

Published Date: 15 March 2024

Experiences of Dermatologists and Patients Regarding Psoriasis and Its Connection to Psoriatic Arthritis in Saudi Arabia

Fatani MI, Al-homood I, Bedaiwi M, Al Natour S, Erdogan A, Alsharafi A, Attar SM

Psoriasis: Targets and Therapy 2024, 14:11-22

Published Date: 18 January 2024

The Skin Microbiome and Its Role in Psoriasis: A Review

Celoria V, Rosset F, Pala V, Dapavo P, Ribero S, Quaglino P, Mastorino L

Psoriasis: Targets and Therapy 2023, 13:71-78

Published Date: 26 October 2023

Management of Plaque Psoriasis in Adults: Clinical Utility of Tapinarof Cream

Spencer RK, Jin JQ, Elhage KG, Davis MS, Liao W, Bhutani T

Psoriasis: Targets and Therapy 2023, 13:59-69

Published Date: 25 October 2023

Palmoplantar Pustulosis: A Systematic Review of Risk Factors and Therapies

Heidemeyer K, May Lee M, Cazzaniga S, Yawalkar N, Naldi L

Psoriasis: Targets and Therapy 2023, 13:33-58

Published Date: 22 September 2023

Therapeutic Management of a Case of Severe Psoriasis Coexistent with Bullous Pemphigoid in the Elderly

Di Lernia V, Peccerillo F, Ficarelli E

Psoriasis: Targets and Therapy 2023, 13:27-31

Published Date: 22 August 2023

Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature

Potestio L, Ruggiero A, Fabbrocini G, Martora F, Megna M

Psoriasis: Targets and Therapy 2023, 13:19-26

Published Date: 4 May 2023

Safety and Efficacy of Covid-19 Vaccination in Patients Undergoing Biological Treatments for Psoriasis

Potestio L, Martora F, Fabbrocini G, Battista T, Megna M

Psoriasis: Targets and Therapy 2023, 13:11-18

Published Date: 12 April 2023

Analysis of Drug Utilization in Patients with Psoriasis: A Real-World Retrospective Study Among the Italian Population

Perrone V, Losi S, Sabatino S, Mezzetti M, Dovizio M, Sangiorgi D, Degli Esposti L

Psoriasis: Targets and Therapy 2023, 13:1-9

Published Date: 2 March 2023

Assessment of Vitamin D Level in Patients with Psoriasis and Its Correlation with Disease Severity: A Case–Control Study

Pokharel R, Agrawal S, Pandey P, Lamsal M

Psoriasis: Targets and Therapy 2022, 12:251-258

Published Date: 13 September 2022

Towards Personalized Medicine in Psoriasis: Current Progress

Camela E, Potestio L, Ruggiero A, Ocampo-Garza SS, Fabbrocini G, Megna M

Psoriasis: Targets and Therapy 2022, 12:231-250

Published Date: 1 September 2022

Therapeutic Inertia in the Management of Psoriasis: A Quantitative Survey Among Indian Dermatologists and Patients

Rajagopalan M, Dogra S, Godse K, Kar BR, Kotla SK, Neema S, Saraswat A, Shah SD, Madnani N, Sardesai V, Sekhri R, Varma S, Arora S, Kawatra P

Psoriasis: Targets and Therapy 2022, 12:221-230

Published Date: 25 August 2022

Reducing the Risk of Developing Psoriatic Arthritis in Patients with Psoriasis

Gisondi P, Bellinato F, Maurelli M, Geat D, Zabotti A, McGonagle D, Girolomoni G

Psoriasis: Targets and Therapy 2022, 12:213-220

Published Date: 10 August 2022

Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study

Megna M, Potestio L, Fabbrocini G, Ruggiero A

Psoriasis: Targets and Therapy 2022, 12:205-212

Published Date: 14 July 2022

Efficacy and Safety of Anti-TNF Biosimilars for Psoriasis in Pediatric and Geriatric Populations: A 72-Week Real-Life Study

Megna M, Fornaro L, Potestio L, Luciano MA, Nocerino M, Delfino M, Guarino M, Fabbrocini G, Camela E

Psoriasis: Targets and Therapy 2022, 12:199-204

Published Date: 9 July 2022

Psoriasis and Exercise: A Review

Yeroushalmi S, Hakimi M, Chung M, Bartholomew E, Bhutani T, Liao W

Psoriasis: Targets and Therapy 2022, 12:189-197

Published Date: 2 July 2022

Dimethyl Fumarate as Therapeutic Alternative in Moderate-to-Severe Psoriasis: Our Experience

Rosés Gibert P, de la Torre Gomar FJ, Saenz Aguirre A, Gimeno Castillo J, González Pérez R

Psoriasis: Targets and Therapy 2022, 12:177-185

Published Date: 29 June 2022

Dietary Intervention and Supplements in the Management of Psoriasis: Current Perspectives

Chung M, Bartholomew E, Yeroushalmi S, Hakimi M, Bhutani T, Liao W

Psoriasis: Targets and Therapy 2022, 12:151-176

Published Date: 22 June 2022

Comorbidity in Adult Psoriasis: Considerations for the Clinician

Daugaard C, Iversen L, Hjuler KF

Psoriasis: Targets and Therapy 2022, 12:139-150

Published Date: 10 June 2022

Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge

Ruggiero A, Potestio L, Camela E, Fabbrocini G, Megna M

Psoriasis: Targets and Therapy 2022, 12:127-137

Published Date: 8 June 2022

Economic Burden of Generalized Pustular Psoriasis in Sweden: A Population-Based Register Study

Löfvendahl S, Norlin JM, Schmitt-Egenolf M

Psoriasis: Targets and Therapy 2022, 12:89-98

Published Date: 5 May 2022

The Effect of Lifestyle Changes on Disease Severity and Quality of Life in Patients with Plaque Psoriasis: A Narrative Review

van Acht MR, van den Reek JMPA, de Jong EMGJ, Seyger MMB

Psoriasis: Targets and Therapy 2022, 12:35-51

Published Date: 9 April 2022

High-Throughput RNA Sequencing Reveals the Effect of NB-UVB Phototherapy on Major Inflammatory Molecules of Lesional Psoriasis

Vacharanukrauh P, Meephansan J, Tangtanatakul P, Soonthornchai W, Wongpiyabovorn J, Serirat O, Komine M

Psoriasis: Targets and Therapy 2021, 11:133-149

Published Date: 26 November 2021

The Use of Apremilast in Psoriasis: An Indian Perspective on Real-World Scenarios

Rajagopalan M, Dogra S, Saraswat A, Varma S, Banodkar P

Psoriasis: Targets and Therapy 2021, 11:109-122

Published Date: 14 August 2021

Key Signaling Pathways in Psoriasis: Recent Insights from Antipsoriatic Therapeutics

Ben Abdallah H, Johansen C, Iversen L

Psoriasis: Targets and Therapy 2021, 11:83-97

Published Date: 29 June 2021

Updates on the Treatment of Erythrodermic Psoriasis

Lo Y, Tsai TF

Psoriasis: Targets and Therapy 2021, 11:59-73

Published Date: 9 June 2021

Association of HLA Alleles and HLA Haplotypes with Psoriasis, Psoriatic Arthritis and Disease Severity in a Miscegenated Population

Cassia FF, Cardoso JF, Porto LC, Ramos-e-Silva M, Carneiro S

Psoriasis: Targets and Therapy 2021, 11:41-51

Published Date: 10 May 2021

Frequency of Health Care Resource Utilization and Direct Medical Costs Associated with Psoriatic Arthritis in a Rheumatic Care Center in Colombia

Santos-Moreno P, Gómez-De la Rosa F, Parra-Padilla D, Alvis-Zakzuk NJ, Alvis-Zakzuk NR, Carrasquilla-Sotomayor M, Valencia O, Alvis-Guzmán N

Psoriasis: Targets and Therapy 2021, 11:31-39

Published Date: 18 March 2021

Phosphodiesterase-4 Inhibition in Psoriasis

Milakovic M, Gooderham MJ

Psoriasis: Targets and Therapy 2021, 11:21-29

Published Date: 17 March 2021

Off-Label Treatments for Pediatric Psoriasis: Lessons for the Clinic

Haulrig MB, Zachariae C, Skov L

Psoriasis: Targets and Therapy 2021, 11:1-20

Published Date: 11 February 2021

A Successful Treatment of Ostraceous Psoriasis Associated with Psoriatic Arthritis in Children: A Case Report

Rowawi R, Dwipangestu G, Suwarsa O, Dharmadji HP, Sutedja E, Pangastuti M, Gunawan H

Psoriasis: Targets and Therapy 2020, 10:61-66

Published Date: 30 December 2020

CMV Infection: A Clinical Challenge in Biological Therapy? The Case of Asymptomatic Patients with Persistent Positive Immunoglobulin M Anti-CMV Treated with Secukinumab

Gambardella A, Licata G, Calabrese G, De Rosa A, Pagliuca F, Alfano R, Argenziano G

Psoriasis: Targets and Therapy 2020, 10:57-60

Published Date: 27 November 2020

More articles